natgillin/translations-raw huggingface dataset:
Respiratory reactions
Okužbe dihal
Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta-blockers.
Po uporabi nekaterih očesnih antagonistov adrenergičnih receptorjev beta so opazili neželene učinke na dihala, vključno s smrtjo zaradi bronhospazma pri bolnikih z astmo.
Respiratory status, blood pressure, fluid balance and weight throughout and immediately after the 5 day clofarabine administration period.
Respiratorni status, krvni tlak, ravnotežje tekočin in telesno maso ves čas 5-dnevnega obdobja dajanja klofarabina in takoj po njem.
Respiratory symptoms (dyspnoea) Respiratory symptoms (bronchospasm)
dihalni simptomi (dispneja) dihalni simptomi (bronhospazem)
Respiratory system
Dihala
Respiratory system bleedingsf
krvavitev v dihalihf
Respiratory system disorders
Bolezni dihal
respiratory tract
dihalnih poti,
respiratory tract
okužba zgornjih
Respiratory tract (sinuses, throat and chest) infection
okužba dihal (sinusov, grla in prsnega koša)
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, eosinophilic pneumonia
bronhospazem, intersticijski pnevmonitis, eozinofilna pljučnica
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, eosinophilic pneumonia
Krvavitve v dihalih (hemoptiza, pljučna krvavitev), bronhospazem, intersticijski
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, eosinophilic pneumonia
Krvavitve v dihalih (hemoptiza, pljučna krvavitev), bronhospazem, intersticijski pnevmonitis, eozinofilna plučnica
Respiratory tract congestion
kongestija dihal
Respiratory tract congestion, such as stuffy nose and sore throat, has been reported in patients with kidney disease not yet on dialysis.
Pri bolnikih z boleznijo ledvic, ki niso na dializi, so poročali o kongestiji dihal, kot je zamašen nos ali bolečine v grlu
Respiratory tract congestion, such as stuffy nose and sore throat, has been reported in patients with kidney disease not yet on dialysis.
Pri bolnikih z boleznijo ledvic, ki se ne zdravijo z dializo, so poročali o kongestiji dihal, kot sta zamašen nos ali boleče grlo.
Respiratory tract congestion, which includes events of upper respiratory tract congestion, nasal congestion and nasopharyngitis, have been reported in studies with extended interval dosing in adult patients with renal insufficiency not yet undergoing dialysis.
V študijah s podaljšanim intervalom odmerjanja pri odraslih bolnikih z ledvično insuficienco, ki se ne zdravijo z dializo, so poročali o kongestiji dihal, ki je vključevala dogodke kongestije zgornjih dihal, kongestije nosne sluznice in nazofaringitis.
Respiratory tract Dyspnoea, cough, sore throat, adult respiratory distress syndrome, respiratory failure
Dihala oteženo dihanje, kašelj, vneto grlo, respiratorni distresni sindrom pri odraslih, respiratorna odpoved
Respiratory tract haemorrhage
krvavitve v dihalih
Respiratory tract infection
okužba dihal
Respiratory tract infection
okužba dihal,
Respiratory tract infection (any infection of the sinuses, throat, airways or lungs)
okužba dihal (kakršna koli okužba sinusov, žrela, dihalnih poti ali pljuč);
Respiratory tract infection (infection of the airways)
okužba dihal (okužba dihalnih poti),
Respiratory tract infection Influenza
okužba dihal gripa
Respiratory tract infection, Vulvovaginal candidiasis, Oral Candidiasis
okužba dihal, kandidoza vulve in nožnice, kandidoza ustne sluznice
respiratory tract infection. changes in blood test to determine if Bosulif is affecting your liver.
okužba dihalnih poti spremenjeni izvidi krvnih preiskav pri ugotavljanju vpliva zdravila Bosulif na jetra
Respiratory tract infectiona
okužba dihala
Respiratory tract infections
Okužbe dihal
Respiratory tract infections (excluding Pneumonia)
okužbe dihal (brez pljučnice)
respiratory tract infections (excluding pneumonia)
okužbe dihalnih poti (razen pljučnice)
respiratory tract infections (including cold, runny nose, sinus infection, pneumonia)
okužbe dihalnega trakta (vključno s prehladom, izcedkom iz nosu, okužbo sinusov, pljučnico)
respiratory tract infections (including cold, runny nose, sinus infection, pneumonia);
okužbe dihalnega trakta (vključno s prehladom, izcedkom iz nosu, okužbo sinusov, pljučnico),
respiratory tract infections (including cold, runny nose, sinus infection, pneumonia);
okužbe dihalnega trakta (vključno s prehladom, izcedkom iz nosu, okužbo sinusov, pljučnico);
respiratory tract infections (including lower and upper respiratory tract infection, pneumonia, sinusitis, pharyngitis, nasopharyngitis and pneumonia herpes viral)
okužbe respiratornega trakta (vključno z okužbo spodnjega in zgornjega respiratornega trakta, pljučnico, vnetjem sinusa, vnetjem sluznice žrela, vnetjem nosnega dela žrela in pljučnim virusnim herpesom)
Respiratory tract infections (upper tract) caused by susceptible strains of Staphylococci, E. coli, and
Okužbe dihalnih poti (zgornjih dihal), ki jih povzročajo občutljivi sevi stafilokokov, E. coli in
Respiratory tract infections (upper tract) caused by susceptible strains of Staphylococci, E. coli, and
Okužbe dihalnih poti (zgornjih), ki jih povzročajo občutljivi sevi stafilokokov, E. coli in
Respiratory undesirable effects commonly occurred in clinical studies of Caelyx and may be related to opportunistic infections in the AIDS population.
Neželeni učinki na dihala so bili v kliničnih raziskavah z zdravilom Caelyx pogosti in so morda povezani z oportunističnimi okužbami pri bolnikih z aidsom.
Respiratory,
Bolezni dihal,
Respiratory,
Bolezni sečil
Respiratory,
pireksija,
Respiratory,
Zelo pogosti
RESPIRATORY, THORACIC
BOLEZNI DIHAL, PRSNEGA
Respiratory, thoracic and
Bolezni dihal, prsnega koša
Respiratory, thoracic and
Bolezni dihal, prsnega koša in
Respiratory, thoracic and
Bolezni dihal, prsnega koša in mediastinalneg a prostora
Respiratory, thoracic and
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory, thoracic and mediastinal
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša iin
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in media- stinalnega prostora
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in media-stina lnega prostora
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinal nega prostora
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinal- nega prostora
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinaln ega prostora
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalne ga prostora
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalne- ga prostora
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalneg
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalnega prostoras
Respiratory, thoracic and mediastinal disorders
Bolezni kože in podkožja
Respiratory, thoracic and mediastinal disorders
Bolezni krvi in limfatičnega sistema
Respiratory, thoracic and mediastinal disorders
Bolezni mišično- skeletnega
Respiratory, thoracic and mediastinal disorders
Bolezni prebavil
Respiratory, Thoracic and Mediastinal Disorders
Bolezni živčevja
Respiratory, thoracic and mediastinal disorders
dihal, prsnega koša
Respiratory, thoracic and mediastinal disorders
Infekcijske in parazitske bolezni
Respiratory, thoracic and mediastinal disorders
prsnega koša in mediastinalnega prostora
Respiratory, thoracic and mediastinal disorders
Respiratorne, torakalne in mediastinalne bolezni:
Respiratory, thoracic and mediastinal disorders haemothorax
Bolezni dihal, prsnega koša in mediastinalnega prostora hemotoraks
Respiratory, thoracic and mediastinal disorders Rare:
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory, thoracic and mediastinal disorders Uncommon: Cough
Bolezni dihal, prsnega koša in mediastinalnega prostora Občasni: kašelj
Respiratory, thoracic and mediastinal disorders Uncommon: Dyspnoea
Bolezni dihal, prsnega koša in mediastinalnega prostora Občasni: dispneja
Respiratory, thoracic and mediastinal disorders Uncommon: Dyspnoea, cough
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory, thoracic and mediastinal disorders*
Bolezni dihal, prsnega koša
Respiratory, thoracic and mediastinal disorders:
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory, thoracic and mediastinal disorders: common: bronchitis uncommon: respiratory disorder
Bolezni dihal, prsnega koša in mediastinalnega prostora: pogosti: bronhitis občasni: težave z dihanjem
Respiratory, thoracic and mediastinal disorders: Gastrointestinal disorders:
Bolezni dihal, prsnega koša in mediastinalnega prostora: Bolezni prebavil:
Respiratory, thoracic and mediastinal disorders: glaucoma
Bolezni dihal, prsnega koša in mediastinalnega prostora:
Respiratory, thoracic and mediastinal disorders: Not known
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory, thoracic and mediastinal disorders: Not known:
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory, thoracic and mediastinal system disorders
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory, Thoracic and Medistinal Disorders
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory, thoracic, and mediastinal disorders
Bolezni dihal, prsnega koša in
Respiratory, thoracic, and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalne ga prostora
Respiratory, thoracic, and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalneg a prostora
Respiratory, thoracic, and mediastinal disorders
Bolezni živčevja
Respiratory, thoracic, or mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory, tThoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalnega prostora
Respiratory: Constriction of the airways in the lungs (predominantly in patients with pre- existing disease) shortness of breath or difficulty breathing, cold symptoms, chest congestion, sinus infection, sneezing, stuffy nose, dry nose, runny nose, nose bleeds, asthma, throat irritation.
Dihala: zožitev dihalnih poti v pljučih (predvsem pri bolnikih z obstoječo boleznijo), zasoplost ali težave z dihanjem, simptomi prehlada, zastajanje tekočine v prsni votlini, okužba sinusov, kihanje, zamašen nos, suh nos, izcedek iz nosu, krvavitev iz nosu, astma, draženje žrela.
Respiratory: constriction of the airways in the lungs (predominantly in patients with pre-existing disease), difficulty breathing, stuffy nose.
Dihala: zožitev dihalnih poti v pljučih (predvsem pri bolnikih z obstoječo boleznijo), težave z dihanjem, zamašen nos
Responded
Nestratificirano
Responded
Odzivni
Responder analyses
Analize bolnikov, ki so se odzivali na zdravljenje
Responder analyses (post-hoc) (e) n(%)
Analize odziva (post-hoc) (e) n (%)
Responder Analysis
Analiza vključenih
Responder Analysis
Analiza vključenih v
Responder rate
Delež odzivnih
Responder rate (secondary endpoint)
Delež odzivnih (sekundarni opazovani dogodek)
Responder rate at week 8
Stopnja odziva po 8 tednih
Responder rate was defined as at least a 3-point improvement in modified Teacher’s Drooling Scale (mTDS).
Stopnja odziva je bila opredeljena kot izboljšanje v višini vsaj treh točk po prilagojeni lestvici slinjenja Teacher's Drooling Scale (mTDS).
Responder rates
Deleži odzivnih bolnikov
Responder, n (%)
(N = 211)
Responder, n (%)
Preiskovanci, ki se
Responders
Odzivni bolniki
responders
pegIFN/RBV
Responders (%)
Odzivne osebe (%)
Responders (Response rate2)
Bolnice z odgovorom na zdravljenje (delež)2
Responders were defined as having more than 50% reduction in the frequency of clonic (or tonic- clonic) seizures during the second month of the double-blind period compared with baseline.
Kot odziv so šteli najmanj 50 % znižanje pogostnosti kloničnih (ali tonično-kloničnih) napadov v drugem mesecu dvojno slepega dela raziskave v primerjavi z izhodiščnim obdobjem.
Responders* N (%)
Bolniki z odzivom* število (%)
Responders*** 95% CI for ORR
95-% interval zaupanja za ORR Popolni odgovor (CR)
Responders, % of patients
Bolniki s kliničnim odzivom v
Responders, % of patients
Bolniki, ki so se odzvali na zdravljenje, % bolnikov
Responders, % of patients
Odzivni, % bolnikov
Responders, % of patients
Začetna vrednost
Responders, n (%)
Odzivne osebe, n (%)
Responders, n (%)
Odzivni bolniki, n (%)
Respons e (%)
Odziv (%)
Response
62,6
Response
Parameter odziva
Response
Virološki neuspeh
Response (%)
Odziv (%)
Response (95% CI)
odziv (95-odstotni IZ)
response (CHR)
odziv (CHR)
response (months) (95 %CI)
(meseci) (95-% IZ)
response (months) (95 %CI)
odgovora (meseci) (95-% IZ)
response *
odziv
Response and remission rates were also higher with Duloxetine Lilly compared to placebo.
Ob uporabi zdravila Duloxetine Lilly v primerjavi s placebom so bile višje tudi stopnje odziva in remisije.
Response and remission rates were also statistically significantly higher with Cymbalta compared with placebo.
Ob uporabi zdravila Cymbalta v primerjavi s placebom so bile značilno višje tudi stopnje odziva in remisije.
Response and remission rates were also statistically significantly higher with duloxetine compared with placebo.
Ob uporabi duloksetina v primerjavi s placebom so bile značilno višje tudi stopnje odziva in remisije.
Response and remission rates were also statistically significantly higher with duloxetine compared with placebo.
Ob uporabi zdravila Duloksetin Mylan v primerjavi s placebom so bile značilno višje tudi stopnje odziva in remisije.
Response and remission rates were also statistically significantly higher with Duloxetine Lilly compared with placebo.
Ob uporabi zdravila Duloxetine Lilly v primerjavi s placebom so bile značilno višje tudi stopnje odziva in remisije.
Response and remission rates were also statistically significantly higher with Xeristar compared with placebo.
Ob uporabi zdravila Xeristar v primerjavi s placebom so bile značilno višje tudi stopnje odziva in remisije.
Response at end of
Odziv na koncu
Response at Positive treatment Sustained predictive week response value
Odziv v Pozitivna tednu Trajni napovedna zdravljenja odziv vrednost
Response by Baseline HIV-1 RNA
Odziv po izhodiščni HIV-1 RNA
Response by subcategory
Odzivi po podkategorijah
Response category (follicular lymphoma)* CR
Kategorija odziva (folikularni limfom)* CR
Response criteria were HBV virological suppression (HBV DNA
Kriteriji odziva so bili zavrtje virusa HBV (HBV DNA
Response defined as decrease from baseline in PANSS Total Score ≥ 20%
Odgovor je opredeljen kot zmanjšanje skupnega rezultata PANSS za ≥ 20% od izhodiščne vrednosti.
Response duration§,#,Þ
Trajanje odgovora§,#, Þ
Response Evaluable Population
Odgovor preiskovane populacije
Response in Clinical Global Functioning Measures
Odziv pri kliničnih merilih splošnega delovanja
Response Not Evaluable (NE)
odziva ni mogoče oceniti (NE)
Response over 12 weeks in the LIR group
Odziv v 12 tednih v skupini z LIR
Response rate
Delež odgovora
Response rate
Delež odziva
Response rate
delež odziva (95 % IZ)
Response Rate
Odziv
Response rate
Stopnja odziva
Response rate
stopnja tveganjab (95% CI)
Response rate (%) (95 % CI)
Stopnja odzivnosti (%) (95 % IZ)
Response rate (%) (95% CI)
9,2 (8,1–10,6)
Response rate (%) (95% CI)
Delež odziva (%) (95 % IZ)
Response rate (%) (95% CI)
Stopnja odziva na zdravljenje (%) (95 % IZ)
Response rate (%) (95% CI)
Stopnja odzivnosti (%) (95 % IZ)
Response rate (%) (95% CI)
Stopnja odzivnosti (%) (95% IZ)
Response rate (%)(95 % CI)
Stopnja odzivnosti (%) (95 % IZ)
Response rate (%, CI) at 4 hours after start of treatment
Stopnja odziva (%, CI) po 4 urah po začetku zdravljenja
Response rate (95 %CI)
Delež odgovora
Response rate (95% CI)
Delež odziva
Response rate (95% CI)
delež odziva (95 % IZ)
Response Rate (confidence intervals)*
(intervali zaupanja)
Response rate (CR, nPR, or PR)
odgovor (CR, nPR ali PR)
Response rate (CR, nPR, or PR)
odgovor (CR, nPR, ali PR)
Response rate (for patients with measurable disease)b
Odgovor bolnikov na zdravljenje (pri bolnikih z merljivo boleznijo)b
Response rate (investigator assessed)a (95% CI)
Delež odziva (raziskovalčeva ocena)a (95% IZ)
Response Rate +/- SE (%)
Stopnja odzivnosti +/- SE (%)
Response rate and CR rates analysed using Chi--squared Test.
Delež odgovorov in popolnih odgovorov so analizirali s testom hi-kvadrat.
Response rate and CR rates analysed using Chi-squared Test.
Delež odgovorov in popolnih odgovorov so analizirali s testom hi-kvadrat.
Response rate in patients with chromosomal abnormality
Delež odziva pri bolnikih s kromosomsko nenormalnostjo
Response rate in patients with prior rituximab therapy
Delež odziva pri bolnikih, predhodno zdravljenih z rituksumabom
Response rate of ≥ 60% improvement in mEASI (Primary
Delež odziva z ≥ 60% izboljšanjem mEASI (primarna končna točka)§§
Response rate of ≥ 60% improvement in mEASI (Primary Endpoint)§§
Delež odziva z ≥ 60% izboljšanjem mEASI (primarna končna točka)§§
Response rate of  60% improvement in mEASI (Primary Endpoint)§§
Delež odziva z  60% izboljšanjem mEASI (primarna končna točka)§§
Response Rate, %
Delež odziva,
Response rate, based on the central reviewer assessment, was 35% (13 CR and 43 PR) for the intent-to- treat-population (ITT) n=162.
Po ugotovitvi osrednjega ocenjevalca je bil delež odziva v populaciji, ki so jo želeli zdraviti 35 % (ITT - »intent-to-treat«, n=162) (13 popolno okrevanje in 43 delno okrevanje).
Response rate, based on the central reviewer assessment, was 35% (13 CR and 43 PR) for the intent-to-treat population (ITT) n=162.
Stopnja odziva v populaciji, ki naj bi jo zdravili (ITT) (n = 162) je bila po oceni glavnega pregledovalca 35- odstotna (13 popolni odziv in 43 delni odziv).
Response rate, based on the central reviewer assessment, was 35% (13 CR and 43 PR) for the intent-to-treat-population (ITT) n=162.
Po ugotovitvi osrednjega ocenjevalca je bil delež odziva v populaciji, ki so jo želeli zdraviti 35 % (ITT - »intent-to-treat«, n=162) (13 popolno okrevanje in 43 delno okrevanje).
Response rate, based on the central reviewer assessment, was 35% (13 CR and 43 PR) for the intent-to-treat-population (ITT) population n=162.
Po ugotovitvi osrednjega ocenjevalca je bil delež odziva v populaciji, ki so jo želeli zdraviti 35 % (ITT - »intent-to-treat«, n=162) (13 popolno okrevanje in 43 delno okrevanje).
Response rate, based on the central reviewer assessment, was 35% (13 CR and 43 PR) for the intent-to-treat-populations (ITT) n=162.
Po ugotovitvi osrednjega ocenjevalca je bil delež odziva v populaciji, ki so jo želeli zdraviti 35 % (ITT - »intent-to-treat«, n=162) (13 popolno okrevanje in 43 delno okrevanje).
Response rates after addition of perampanel at fixed doses were less when patients received concomitant CYP3A enzyme-inducing anti-epileptic medicinal products (carbamazepine, phenytoin, oxcarbazepine) as compared to response rates in patient who received concomitant non-enzyme– inducing anti-epileptic medicinal products.
Stopnje odzivnosti po dodajanju perampanela pri fiksnih odmerkih so bile nižje, če so bolniki sočasno prejeli antiepileptična zdravila, ki spodbujajo encim CYP3A (karbamazepin, fenitoin, okskarbazepin) v primerjavi s stopnjo odziva pri bolnikih, ki so sočasno prejeli antiepileptična zdravila, ki ne spodbujajo encimov.
response rates and 95% CI for
in 95 % IZ za razlike med zdravljenji a
Response rates are presented in Table 10.
Deleži odziva so predstavljeni v preglednici 10.
Response rates at the end of follow-up for the two studies are presented in Table 11.
Deleži odzivov po koncu obdobja sledenja bolnikom za ti dve študiji so predstavljeni v preglednici 11.
Response rates at the end of Period A, at the end of Period B and after 5 years exposure in Period C are summarized in Table 8:
Deleži odziva ob koncu obdobja A, ob koncu obdobja B in po 5 letih zdravljenja v obdobju C so povzeti v preglednici 8:
Response rates were 34.6% (95% CI: 24.2, 46.2) for the Votubia arm compared with 0% (95% CI: 0.0, 9.0) for the placebo arm (Table 4).
V skupini z zdravilom Votubia je znašal delež bolnikov z odzivom 34,6 % (95-odstotni IZ: 24,2, 46,2), v skupini s placebom pa 0 % (95-odstotni IZ: 0,0, 9,0) (preglednica 4).
Response rates were 34.6% (95% CI: 24.2, 46.2) for the Votubia arm compared with 0% (95% CI: 0.0, 9.0) for the placebo arm (Table 6).
V skupini z zdravilom Votubia je znašal delež bolnikov z odzivom 34,6 % (95-odstotni IZ: 24,2, 46,2), v skupini s placebom pa 0 % (95-odstotni IZ: 0,0, 9,0) (preglednica 6).
Response rates were similar in each arm, with an overall response rate of 80.7% (95% CI: 70.9; 88.3) and 85.2% (95% CI: 76.1; 91.9) in the MabThera intravenous and subcutaneous arms, respectively.
Deleža odgovorov sta bila v obeh skupinah podobna; delež celokupnega odgovora je bil v skupini z intravensko obliko zdravila MabThera 80,7 % (95-% IZ: 70,9; 88,3) in v skupini s podkožno obliko zdravila Mabthera 85,2 % (95-% IZ: 76,1; 91,9).
Response rates were statistically significantly higher with Thymanax compared with placebo.
Stopnje odziva so bile v skupinah, ki so prejemale zdravilo Thymanax, statistično značilno večje v primerjavi s placebom.
Response rates were statistically significantly higher with Valdoxan compared with placebo.
Stopnje odziva so bile v skupinah, ki so prejemale zdravilo Valdoxan, statistično značilno večje v primerjavi s placebom.
Response to
Odziv na
Response to apremilast was rapid, with significantly greater improvements in the signs and symptoms of psoriasis, including PASI, skin discomfort/pain and pruritus, compared to placebo by Week 2.
Odziv na apremilast je bil hiter, s signifikantno večjim izboljšanjem znakov in simptomov psoriaze po 2 tednih, vključno s PASI, neugodjem/bolečino v koži in pruritusom, v primerjavi s placebom.
Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.
Odzivanje na dolgotrajno zdravljenje mora v rednih razmikih spremljati veterinar.
Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.
Pri dolgotrajni uporabi zdravila je potreben reden nadzor veterinarja.
Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.
Veterinar naj v rednih razmikih spremlja odzivanje na dolgotrajno zdravljenje.
Response to prior HCV treatment
Odziv na predhodno zdravljenje HCV
Response to the treatment was defined as having an average of ≥ 3 spontaneous bowel movements (SBMs) per week and an average number of faecal incontinence episodes of ≤ 1 per 2 weeks.
Odziv na zdravljenje je bil opredeljen kot povprečno tri ali več spontanih odvajanj blata tedensko in povprečno največ ena epizoda fekalne inkontinence na dva tedna.
Response to treatment is determined by a decrease in blood phenylalanine following treatment with Kuvan.
Odziv na zdravljenje se določa z znižanjem ravni fenilalanina v krvi po zdravljenju z zdravilom Kuvan.
Response to treatment was also high in the second study (ranging from 57% to 66%) where Perjeta was given with trastuzumab and different chemotherapy medicines.
Odziv na zdravljenje je bil visok (od 57 % do 66 %) tudi v drugi študiji, kjer so zdravilo dajali v kombinaciji s trastuzumabom in različnimi zdravili za kemoterapijo.
Response to treatment was assessed using body scans and standardised criteria used for solid tumours, with complete response being when the patient had no remaining signs of the cancer.
Odziv na zdravljenje so ocenjevali s slikanjem telesa in standardiziranimi merili, ki se uporabljajo za čvrste tumorje; popoln odziv je pri tem pomenil, da bolnik nima nobenih preostalih znakov raka.